ILMN May 2026 · sell
Illumina remains the dominant player in genomic sequencing but is transitioning into a mature compounder phase. Having resolved recent antitrust distractions and returned to profitability in 2025, the company faces normalized mid-single-digit growth, requiring disciplined capital allocation and margin protection against emerging competitors.
$145.70